ArticlePLoS neglected tropical diseases2013
A high force of plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in papua new guinean children.
Article in PLoS neglected tropical diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 62 citations in OpenAlex.
- Population heterogeneity in Plasmodium vivax relapse risk.PLoS neglected tropical diseases · 2022Trial
- Trial
- Comparison of CD4 T-Cell Response in Plasmodium falciparum and vivax Malaria.The Journal of infectious diseases · 2026Article
- A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria.Immunity · 2026Article
- Cytokine signatures associated with persistent antibody responses to multipleFrontiers in immunology · 2026Article
- The probability of Plasmodium vivax acute illness following primary infection and relapse in Papua New Guinea.PLoS neglected tropical diseases · 2025Article
- Profiling vivax malaria incidence, residual transmission, and risk factors using reactive case detection in low transmission settings of Ethiopia.Malaria journal · 2024Article
- Recurrence patterns and evolution of submicroscopic and asymptomatic Plasmodium vivax infections in malaria-endemic areas of the Peruvian Amazon.PLoS neglected tropical diseases · 2024Article
- A hybrid transmission model for Plasmodium vivax accounting for superinfection, immunity and the hypnozoite reservoir.Journal of mathematical biology · 2024Article
- Identification of novelFrontiers in cellular and infection microbiology · 2023Article
- Prevalence and force of Plasmodium vivax blood-stage infection and associated clinical malaria burden in the Brazilian Amazon.Memorias do Instituto Oswaldo Cruz · 2022Article
- High-dimensional mass cytometry identifies T cell and B cell signatures predicting reduced risk of Plasmodium vivax malaria.JCI insight · 2021Observational
- 10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity.Wellcome open research · 2021Article
- Article
- Early transmission of sensitive strain slows down emergence of drug resistance in Plasmodium vivax.PLoS computational biology · 2020Article
- Differential impact of malaria control interventions on P. falciparum and P. vivax infections in young Papua New Guinean children.BMC medicine · 2019Article
- Antibodies to Plasmodium vivax reticulocyte binding protein 2b are associated with protection against P. vivax malaria in populations living in low malaria transmission regions of Brazil and Thailand.PLoS neglected tropical diseases · 2019Article
- Multiplex serology demonstrate cumulative prevalence and spatial distribution of malaria in Ethiopia.Malaria journal · 2019Article
- Malaria Molecular Epidemiology: An Evolutionary Genetics Perspective.Microbiology spectrum · 2019Review
- Highly heterogeneous residual malaria risk in western Thailand.International journal for parasitology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 5 countries.
Funding
Abstract
backgroundWhen both parasite species are co-endemic, Plasmodium vivax incidence peaks in younger children compared to P. falciparum. To identify differences in the number of blood stage infections of these species and its potential link to acquisition of immunity, we have estimated the molecular force of blood-stage infection of P. vivax ((mol)FOB, i.e. the number of genetically distinct blood-stage infections over time), and compared it to previously reported values for P. falciparum.
methodsP. vivax (mol)FOB was estimated by high resolution genotyping parasites in samples collected over 16 months in a cohort of 264 Papua New Guinean children living in an area highly endemic for P. falciparum and P. vivax. In this cohort, P. vivax episodes decreased three-fold over the age range of 1-4.5 years.
resultsOn average, children acquired 14.0 new P. vivax blood-stage clones/child/year-at-risk. While the incidence of clinical P. vivax illness was strongly associated with mol FOB (incidence rate ratio (IRR) = 1.99, 95% confidence interval (CI95) [1.80, 2.19]), (mol)FOB did not change with age. The incidence of P. vivax showed a faster decrease with age in children with high (IRR = 0.49, CI95 [0.38, 0.64] p<0.001) compared to those with low exposure (IRR = 0.63, CI95[0.43, 0.93] p = 0.02).
conclusionP. vivax (mol)FOB is considerably higher than P. falciparum (mol)FOB (5.5 clones/child/year-at-risk). The high number of P. vivax clones that infect children in early childhood contribute to the rapid acquisition of immunity against clinical P. vivax malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.